J&J Still Battling Levaquin Lawsuits

Johnson and Johnson’s Ortho-McNeil-Janssen Pharmaceutical unit is still under fire in New Jersey state court this week, as closing arguments wrap-up regarding the risks associated with use of the company’s popular antibiotic, Levaquin.

Specifically, plaintiffs allege that the J&J unit never fully warned patients of the serious risk for tendon damage associated with use of Levaquin, compared to rival medications. According to plaintiffs’ counsel, Ortho-McNeil-Janssen sought to protect sales by omitting proper warning information regarding Levaquin’s “comparative risks” on the drug’s label.

This is the third case associated with Levaquin-related tendon injury to go to trial since November, and J&J faces more than 2,600 claims in other U.S. courts.

Bookmark and Share

Comments are closed.